PROK PROKIDNEY CORP

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in November:

Guggenheim Healthcare Innovation Conference (Boston)

Date: Wednesday, November 12, 2025

Time: 10:00am ET

Format: Fireside Chat

Webcast:

Jefferies Global Healthcare Conference (London)

Dates: November 17-20, 2025

Format: 1x1 Meetings

The live webcast of the fireside chat will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at . Investors interested in one-on-one meetings should contact their banking representatives.

About ProKidney Corp.

ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit .

ProKidney Contact

Ethan Holdaway

Media Contact

Audra Friis 

Investor Relations Contact

Daniel Ferry



EN
29/10/2025

Underlying

PROKPROKIDNEY CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROKIDNEY CORP

 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Expands Senior Leadership Team with Appointment of Greg Madi...

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive...

March 25, 2026 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Full Year 2025 Financial Results and Business Highli...

ProKidney Reports Full Year 2025 Financial Results and Business Highlights On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 million in cash ...

March 18, 2026 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Confere...

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 44th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 14, 2026Time: 8:15am PSTFo...

January 6, 2026 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Third Quarter 2025 Financial Results and Provides Re...

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using estimated glomerular filtration rate (eGFR) slope have been enrolled; topline results anticipated in Q2 2027Ended the third quarter with $272 million in cash and cash equivalents and marketable securities,...

November 10, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Ri...

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with rilparencel resulted in a 4.6 mL/min/1.73m2 (78%) improvement in the annual decline of estimated glomerular filtration rate (eGFR) slope in Group 1 (n=24) patientsNo rilparencel-related serious adverse events were observed; the overall study sa...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch